Recruiting NCT04217512
Pantoprazole in Cisplatin Nephrotoxicity
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pantoprazole low dose, Pantoprazole high dose, Standard hydration, Cisplatin.
- Who it may be relevant to
- Registry conditions: Oncology. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Possible Protective Effect of Pantoprazole in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer
Overview
Pantoprazole in Cisplatin Nephrotoxicity
Detailed description
Pantoprazole in Cisplatin NephrotoxicityPantoprazole in Cisplatin Nephrotoxicity. Is it protective?
Interventions
- Drug Pantoprazole low dose
Pantoprazole 0.6 mg/kg - Drug Pantoprazole high dose
Pantoprazole 1.6 mg\\kg - Other Standard hydration
Standard hydration alone - Drug Cisplatin
Cisplatin
Primary outcome measures
- Number of patients with no renal toxicity [Time frame: 6 months]
Eligibility criteria
Inclusion criteria
- Patients with head and neck cancer
Exclusion criteria
- GFR less than 59.
- DM
- Elevated liver enzymes more than 3 fold.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
Egypt · 1 center
- Sherief Abd-Elsalam — Tanta
Identifiers
NCT: NCT04217512 · eman ghoneim